TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.
SPRING HOUSE, PENNSYLVANIA, May 31, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment. | May 31, 2023
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of.
Share this article
SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2
a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA
® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).
1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis
b and dactylitis
1-8 In addition, the extent of radiographic progression
d was studied through two years. These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021.
Biologic approved for plaque psoriasis shows efficacy in PsA patients
Prof
Iain McInnes, the lead author of DISCOVER-2, discusses the latest findings of the phase-3 global trial to assess guselkumab in biologic-naïve patients with psoriatic arthritis.
Peter Doyle reports
Sustained improvements over 52 weeks were noted in biologic-naïve patients with psoriatic arthritis (PsA) who were given a monoclonal antibody against interleukin-23 normally used for the treatment of plaque psoriasis, a recent study is reporting.
In 2017, guselkumab, a human monoclonal antibody specific to interleukin-23p19, was approved to treat adults with moderate-to-severe plaque psoriasis and who were candidates for systemic therapy or phototherapy.